Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. - Wikidata - awgldk - TriplyDB

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

http://www.wikidata.org/entity/Q37601722

about

Approaches to modernize the combination drug development paradigm Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.Precision medicine in breast cancer: reality or utopia?Novel therapeutic strategies in the treatment of triple-negative breast cancer.PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Neratinib for the treatment of HER2-positive early stage breast cancer.MOLECULAR PATHWAYS: TARGETING THE MICROENVIRONMENT OF LIVER METASTASES.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.How the future of clinical cancer diagnostics can contribute to overcoming race-associated cancer disparities.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.Biological Subtypes of Triple-Negative Breast Cancer.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.Spotlight on landmark oncology trials: the latest evidence and novel trial designs.The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.Innovations in Clinical Trial Design in the Era of Molecular Profiling.Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools.PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization.GOLPH3: a novel biomarker that correlates with poor survival and resistance to chemotherapy in breast cancer.University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion).Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients.Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.Exploratory trials in mental health: anything to learn from other disciplines?Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.

P2860

Q28072074-58F84B8C-F00C-46AB-87E0-29C3C0E71E48 Q33440778-E7F33035-42FE-49C5-8F28-6F295A6B66D5 Q33563963-CC2121B4-773D-44A2-AB19-DA3B809D0522 Q33809114-22D46FE1-FF11-45D6-815A-B85D57B9C8BC Q33887682-A1D7F178-A981-413A-BADD-BD98CE26ABC0 Q37481946-0F750AF5-28DC-435F-9EB3-876E7E29F207 Q37607283-EFA0A6A2-8EE5-44FB-8511-AD96B5EECA30 Q37720246-CB0531F8-CDA2-46FB-8659-5EA4F3AA5272 Q38375607-FECC9FE2-B151-4A0A-9C36-63A748C1CD37 Q38661390-C3866179-545A-46C1-A01A-04B1951CF277 Q38666768-C46298EA-8263-4B92-9E36-E8790CE737E0 Q38671001-715BDDB5-0010-44B9-9CAB-8A730B3F0321 Q38683638-8CD3A3E2-B56C-4AD4-8702-6EF6105C2F55 Q38706298-AAA96439-FAB9-49E8-95FC-068DA505F794 Q38803048-146E9C43-0F51-4617-8522-59A5460834EF Q38811820-EA6A9F65-97DF-4C28-9C51-5397C2DAF6A7 Q38919646-8873A0A0-AD72-4209-9027-7843B7B36F0A Q39370768-34E633FF-1633-46BE-B550-6163C232F7A0 Q39375196-C6738212-DD97-429B-826F-43BD9A96EB4E Q41527706-EA4F1EB8-666E-4F70-AD56-C8D847532754 Q41542872-16F152B2-0F4B-42A4-861C-FAB05D38AEA0 Q41595492-F59E03C0-AEC7-43C0-8EC8-BF90A3809B7E Q42332672-B59A6990-7AB0-48FC-92A1-9DC825BD7684 Q42343618-8AB33B37-42A9-479F-AEB8-A07988B650A4 Q42359019-8D74B7AC-8048-4405-B8DC-ED70AB1A6C7D Q42507631-4A257F59-606B-48C7-9F6C-DA5C2889FF9B Q42517340-8E091D0F-FE90-43B2-97C5-E7FA6A09840B Q42673155-188ED165-C6AA-4B34-BC30-29A9B2EB7A88 Q45059047-6D0E16C7-4B55-45DB-99B4-F574A2A5CD03 Q47110708-FA9344E9-869B-43FB-8C15-6FFEE659F945 Q47156777-E5BC1A2F-AB40-4F00-903C-985A5CA34574 Q47161478-97D936FE-A6F5-46F1-90C6-BBEE5AFD0F15 Q47304892-C00D84D0-7FD0-4B24-A1EB-D06C741D7821 Q47372927-B457B8A6-DB07-441B-AB13-51BAD6B0502B Q47397566-86BB3C83-A6CE-4771-A4B1-C4A4CACCC6A5 Q47406496-9CBFF540-9A6F-4AA5-BA4E-3FF9E9FE85C2 Q47621328-1678DA29-C391-41D8-9FD1-9CC5F2815211 Q47832169-91D37EDC-92E0-48FD-9BCA-F04920CA2CE6 Q48023755-C1F005D2-624A-46E3-8C76-3162C46FC62A Q48165156-F17229AA-A4C6-4C53-BB41-082648688577

P2860

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

http://www.wikidata.org/entity/Q37601722

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

@en

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

@nl

type

label

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

@en

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

@nl

prefLabel

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

@en

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

@nl

P1433

Q37601722-B818B4A0-E495-4616-94FE-B404AB424824

P1476

Q37601722-5756646C-D5C8-4576-98BB-84F46DC286E2

P2093

Q37601722-014D8B44-A0D8-40A5-88AE-C703B81B8E26

Q37601722-0C21B511-B1F1-4061-B40D-2D4F9E263A9D

Q37601722-104D5D60-2E4C-4B13-A2E5-989F4A842F0D

Q37601722-1C5828A5-0765-413D-A2FF-004CF07A517F

Q37601722-24A50E8D-B8A0-4EB0-B0ED-8F9F6CA1A0A3

Q37601722-29464180-2186-4EDE-8634-31F8ECF1739C

Q37601722-3212A1C9-136F-4620-B553-38DBA61AFDB9

Q37601722-346621B5-7FE8-40E2-966A-5531FE7E185B

Q37601722-3BE1B49F-4952-44D9-B9CB-1E00EF7F0306

Q37601722-4A92BDF8-1AD8-42D5-BBB0-806F3F08EC6D

P2860

Q37601722-0B6995D7-F282-48D1-A679-76AEE3C886A6

Q37601722-11BA8A79-9E5B-474C-8942-1BC3D2C74353

Q37601722-1667DEB5-CB85-4DDD-8C1E-8606327DBBEE

Q37601722-357904C9-C9DF-4948-8BCC-5D5EAF962979

Q37601722-360F80C2-5B3E-4E58-9C9C-3BC957C27191

Q37601722-512A52B5-198E-42BA-807A-90102DADDB42

Q37601722-63807B1E-51AF-44E5-8392-3D6F89467F55

Q37601722-761EDE80-B923-4AF1-BF1E-6A8FC6776977

Q37601722-7714276F-442D-4AB0-AFE6-711A4AABD1F0

Q37601722-7B5D84FB-B5D0-41F1-B0B5-4A0CA4754016

P304

Q37601722-7644624B-DF67-488C-BBE2-C458CD3628E9

P31

Q37601722-D2CA3023-F63E-4D7C-AD33-96F3B30C04A7

P356

Q37601722-2F351881-8723-45AF-8AD2-5C0240F35F6A

P407

Q37601722-559ABDAB-6271-4533-85EB-B44D3291C0BA

P433

Q37601722-F4B1D36A-5EEC-490D-B0E3-A5FBA9CA9575

P478

Q37601722-4DD66365-23A8-42A1-A33E-EAE573C4E062

P50

Q37601722-43960BAD-7A76-4FB4-97EB-44D532E33436

Q37601722-6B9215C1-72FE-4F77-B6C3-0EFA729699D5

P577

Q37601722-90DD580C-0528-49A5-ABE0-0650AEFBFB87

P698

Q37601722-9ACDB714-B6D9-446C-BE46-BE295E873B54

P932

Q37601722-378C5181-ABC0-4EA2-9B0E-06D9E9C4BA5B

P356

P1433

The New England Journal of Medicine

P1476

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

@en

P2093

A Jo Chien

http://www.w3.org/2001/XMLSchema#string

Angela DeMichele

http://www.w3.org/2001/XMLSchema#string

Anne M Wallace

http://www.w3.org/2001/XMLSchema#string

Anthony D Elias

http://www.w3.org/2001/XMLSchema#string

Ashish Sanil

http://www.w3.org/2001/XMLSchema#string

Barbara B Haley

http://www.w3.org/2001/XMLSchema#string

Cheryl Ewing

http://www.w3.org/2001/XMLSchema#string

Christina Yau

http://www.w3.org/2001/XMLSchema#string

David M Euhus

http://www.w3.org/2001/XMLSchema#string

Debasish Tripathy

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Role of PARP inhibitors in cancer biology and therapy

Bayesian clinical trials.

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

P304

23-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1513749

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Olufunmilayo Olopade

Claudine Isaacs

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27406347

http://www.w3.org/2001/XMLSchema#string

P932

5259561

http://www.w3.org/2001/XMLSchema#string